TrialA Phase 2A Trial of DT402 for Autism Spectrum Disorder
Trial details
- Registry ID
- NCT07303907
- Phase
- Phase 2
Drug research
DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as MDMA; MM402; R-MDMA
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2A Trial of DT402 for Autism Spectrum DisorderNCT07303907 | Definium Therapeutics US, Inc. | Phase 2 | Recruiting | 2027-08Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |